title: Nimodipine in migraine prophylaxis.
abstract: Nimodipine is a compound that is thought to block the influx of calcium through channels in vascular smooth muscle. This paper describes a double-blind parallel-group comparison of 40 mg nimodipine three times a day and placebo. Sixty-eight patients received treatment after a run-in period of 2 months, and of these, 57 completed 8 weeks or more of the trial. All but five of these completed the full 6-month trial. The nimodipine and placebo groups showed no significant differences in the frequency of attacks, severity or duration of headache, or gastrointestinal or other symptoms.
authors.affiliation: City of London Migraine Clinic, UK.
authors.forename: E
authors.initials: E
authors.lastname: Ansell
authors.forename: T
authors.initials: T
authors.lastname: Fazzone
authors.forename: R
authors.initials: R
authors.lastname: Festenstein
authors.forename: E S
authors.initials: ES
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Thavapalan
authors.forename: M
authors.initials: M
authors.lastname: Wilkinson
authors.forename: I
authors.initials: I
authors.lastname: Wozniak
mesh_terms: D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D009553:Nimodipine / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D009553:Nimodipine